Table 1.
Demographics, disease and treatment history (n=15)
| Characteristics | |
|---|---|
| Male | 10 (67%) |
| Right handed | 13 (87%) |
| Age at study entry, years | |
| Mean (SD) | 58.9 (14.1) |
| Median (range) | 53 (43–85) |
| Mean education, years (SD) | 15.3 (3.1) |
| Mean estimated VIQ (SD) | 113 (6.8) |
| Mean MMSE scorea (SD) | 26.7 (2.3) |
| Working at study entry | 6 (40%) |
| Tumor type | |
| Low Grade Glioma | 2 (13%) |
| High Grade Glioma | 5 (34%) |
| Primary CNS Lymphoma | 6 (40%) |
| Other | 2 (13%) |
| Tumor location | |
| Frontal/temporal | 7 (47%) |
| Parietal/occipital | 2 (13%) |
| Cortical/subcortical | 6 (40%) |
| Predominant tumor side | |
| Left | 7 (47%) |
| Right | 6 (40%) |
| Bilateral | 2 (13%) |
| Treatment typeb | |
| RT + Chemotherapy | 12 (80%) |
| Chemotherapy | 3 (20%) |
| Time since treatment completion, months | |
| Mean (SD) | 70 (55) |
| Median (range) | 47 (7–161) |
| Anticonvulsantsc | |
| Monotherapy | 7 (47%) |
| Polytherapy | 2 (13%) |
| None | 6 (40%) |
SD standard deviation; VIQ verbal IQ (North American adult reading test or barona index)
a
MMSE=Mini-Mental Status Examination at baseline;
b
Treatment history reflects all therapy received including treatment at relapse, if applicable; RT=Radiotherapy;
c
Medication throughout study participation